Burioni Roberto, Perotti Mario, Mancini Nicasio, Clementi Massimo
Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Istituto Scientifico San Raffaele, San Raffaele Diagnostica e Ricerca, Milan, Italy.
J Hepatol. 2008 Aug;49(2):299-300. doi: 10.1016/j.jhep.2008.05.008. Epub 2008 May 23.
A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.
丙型肝炎病毒（HCV）免疫疗法或疫苗设计中的一个主要问题是该病毒的高度变异性。我们鉴定出了能中和基因多样的HCV分离株并在人肝嵌合小鼠模型中抵御异源HCV准种攻击的人单克隆抗体（mAb）。这些结果证明了针对HCV的广泛中和抗体可抵御异源病毒感染，并表明针对HCV的预防性疫苗或许是可以实现的。
